Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Replimune, Inc.

Clinical trials sponsored by Replimune, Inc., explained in plain language.

Replimune, Inc. REPL NASDAQ

Biopharmaceutical company developing oncolytic immunotherapies.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 4 Not yet finished but already full! 5 Terminated 1

Virus therapy fails to advance in colorectal cancer trial

Disease control Terminated

This study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…

Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control

Last updated Jun 27, 2026 09:01 UTC